AnaptysBio uses its proprietary SHM-Platform to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. Its product candidates include rosnilimab, ANB032, and ANB033. AnaptysBio has also discovered antibodies licensed to GSK in a financial collaboration for immune-oncology. The entity generates revenue from collaborative research and development arrangements.